Form 483 Reply Can Be Ticket To FDA’s Good Side – Attorney
This article was originally published in The Tan Sheet
Taking a conciliatory tone and showing a commitment to compliance can help a company avoid further enforcement action after receiving a form 483 from FDA that details “significant” inspectional observations, says food and drug attorney Kate Beardsley.
You may also be interested in...
After A Brief Pause, Injectables Cash Cow Agila Is Back Into Production; Pfizer Expects Shipping To Commence Soon
Agila, as its name suggests, was agile in correcting deficiencies outlined in an FDA 483 last month and is back on track to supply global customers like Pfizer, GSK and Eli Lilly. But Mylan’s planned buyout of Agila, Strides Arcolab’s cash cow, has hit a snag and been put on hold by India’s finance ministry.
A substantive and timely response to a form 483 can help a firm avoid or mitigate further FDA enforcement action, a senior agency official says.
NaZura BioHealth, spun out from Elcelyx Therapeutics, will market its Lovidia weight-loss product in 2014 when it launches into the direct-response channel, before potential suitors get serious about acquiring the brand.